Skip to content
Open access

Imaging Cancer Immunity

Abstract

This thesis contributes to the development and validation of positron emission tomography (PET) tracers targeting the cancer immune system for use in clinical research and oncology drug development. The work is divided into three parts: validation of the immune-cell tracer [¹⁸F]F-AraG, quantitative assessment of target engagement using ⁸⁹Zr-labelled monoclonal antibodies, and evaluation of PET biomarkers for treatment response and immune modulation. The first part focused on the validation of [¹⁸F]F-AraG PET as a pharmacodynamic biomarker of immune activation. Pharmacokinetic analyses demonstrated that tracer uptake is best described by a two-tissue irreversible compartment model, with the net influx rate constant (Ki) as the preferred quantitative measure. Simplified uptake measures correlated well with kinetic modelling results, with the tumour-to-plasma ratio emerging as the preferred simplified metric. The tracer’s pharmacokinetic characteristics were consistent across different tumour types and during combined immunotherapy. [¹⁸F]F-AraG was safely administered without tracer-related adverse events. Biological analyses showed that changes in tracer uptake corresponded with changes in functional (non-exhausted) cytotoxic T-cels during treatment, and clinical observations suggest associations between tracer uptake patterns and treatment response. Together, these findings support continued validation of [¹⁸F]F-AraG PET as a biomarker of immune-cell infiltration and activation. The second part examined the use of ⁸⁹Zr-labelled monoclonal antibodies for assessing biodistribution, target engagement, and target blockade in vivo. Clinical studies with radiolabelled antibodies demonstrated that a substantial proportion of PET signal originates from non-specific processes, including plasma distribution and antibody catabolism. To address this, a quantitative framework was developed that corrects tissue uptake for non-specific antibody accumulation. Application of this method with a SIRPα-targeting antibody enabled more specific assessment of target-mediated uptake and demonstrated target engagement in both healthy organs and tumours. Blockade studies further confirmed target-specific binding. These methodological developments improve the quantitative interpretation of immunoPET data and strengthen the use of ⁸⁹Zr-labelled antibodies as biomarkers in drug development. The third part evaluated PD-L1 PET imaging as a biomarker for treatment response and immune regulation. Previously published studies reported generally higher baseline PD-L1 PET uptake in tumour lesions of patients who subsequently responded to anti-PD(L)1 therapy. Analysis of non-tumour tissues as part of this thesis identified differences in PD-L1 tracer uptake between responding and non-responding patients, particularly in the spleen and bone marrow. Evaluation of lymph nodes demonstrated distinct uptake patterns in tumour-draining lymph nodes compared with non-tumour-draining and malignant lymph nodes. These findings indicate that PD-L1 PET reflects both tumour-specific and systemic immune processes and may provide complementary information for patient stratification and response assessment. In conclusion, this thesis advances the development of immune oncology PET by providing evidence for the validation of [¹⁸F]F-AraG PET as a biomarker for in vivo immune activation, illustrating how correction for antibody catabolism can support quantification of target-specific uptake of ⁸⁹Zr-labelled antibodies, and exploring the clinical value of PD-L1 PET imaging. Collectively, these studies demonstrate the potential of immunoPET to support mechanistic understanding, target engagement assessment, dose selection, treatment response prediction, and response monitoring in oncology drug development.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.